If you would like to ask our webinar guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksValiRx Share News (VAL)

Share Price Information for ValiRx (VAL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.05
Bid: 3.00
Ask: 3.10
Change: -0.05 (-1.61%)
Spread: 0.10 (3.333%)
Open: 3.10
High: 3.15
Low: 3.05
Prev. Close: 3.10
VAL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EARNINGS AND TRADING: Ten Lifestyle sees profit up but sales flat

Tue, 19th Mar 2024 19:47

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

----------

TMT Investments PLC - venture capital investor in high-growth technology companies - Reports net asset value per share of USD6.62 in the year ending December 31, rising 3.3% from USD6.41 the year prior. Total NAV rose to USD208.1 million from USD201.7 million. Explains improvement was mainly as a result of the upward revaluation of Backblaze and Collectly during the period. "With no financial debt and cash and cash equivalent reserves of USD11.0 million," TMT is "well positioned to ride out the current market volatility and to continue making investments and realising full and partial disposals when the right opportunities present themselves."

----------

Ten Lifestyle Group PLC - London-based lifestyle and travel services company - Issues trading update for six months to February 29. Expects to report half year net revenue of around GBP30.9 million, unchanged from last year, or up 4% at constant currency. Says active members continue to grow, up 13% to 356,000 from 316,000 last year. Explains the group secured and launched some significant contracts during the period that are expected to generate revenue in the second half of the year. Adjusted earnings before interest, tax, depreciation and amortisation is expected to be around GBP5.3 million, up from GBP5.0 million last year. At the end of the first half, says cash and cash equivalents were GBP8.0 million, compared to GBP8.2 million at the previous year-end.

----------

First Class Metals PLC - Ontario, Canada-focused exploration company - Signs sixty day exclusivity agreement with Emerald Geological Services Ltd in respect of an earn-in to the McInnes Lake Property in Ontario. Chief Executive Marc Sale comments: "This is an exciting development for FCM greenfield exploration opportunities on a property which potentially contains the same structure that is present at Red Lake. The lack of previous systematic or comprehensive exploration in a favourable geological setting presents realistic expectation for a significant discovery." Pays CAD5,000, around GBP2,897, for the exclusivity period.

----------

ValiRx PLC - Nuneaton, England-based life sciences company focused on early-stage cancer therapeutics - Starts search for a chief executive officer to lead the next stage of growth. Expects the process may take a number of months, during which period Suzy Dilly will remain as CEO. As part of the re-structuring process, Dilly and the board will consider potential alternative roles. In addition, Adrian de Courcey joins the board as non-executive director.

----------

Atlantic Lithium Ltd - lithium development company, currently focused on developing the Ewoyaa project on the Ghanaian coast - Announces further broad and high-grade assay results from resource drilling completed at the Ewoyaa lithium project in Ghana. Notes multiple high-grade and broad extensional drill intersections reported at the new Dog-Leg target. Describes results at Dog-Leg as "significant". Points out drilling has intersected shallow dipping, near surface mineralised pegmatite bodies with true thicknesses up to 35m outside of the mineral resource estimate, proving potential for significant resource growth. Plans to advance the drilling programme to be undertaken in 2024. A mineral resource estimate upgrade, for both lithium and feldspar, to incorporate all 2023 and 2024 drilling, is targeted for the second half of 2024.

----------

Evgen Pharma PLC - clinical stage drug development company developing sulforaphane-based medicines - Agrees to buy Chronos Therapeutics Ltd for initial GBP899,481, or 1.44 pence per share. Explains price could rise to GBP3.4 million subject to the achievement of certain milestones. Chronos features a neuropsychiatry portfolio including two assets developed to late pre-clinical stage. Further, raises GBP0.85 million via placing and subscription at 1p each. In addition, announces retail offer to raise up to GBP1 million. Proceeds of the fund raise will be used for working capital and to maintain the enlarged group's patent portfolio. Plans name change to TheraCryf PLC.

----------

Impellam Group PLC - Luton, England-based specialist recruitment solutions provider - Says High Court sanctions scheme by which bid from HeadFirst Global BV will be facilitated. Expects scheme to become effective on Thursday, when shares will also be suspended.

----------

Custodian Property Income Reit PLC - real estate investment trust - Shareholders back resolution allowing company to allot shares or grant rights to subscribe for or convert any security into shares in the company in connection with the recommended merger with abrdn Property Income Trust Ltd. Chair David MacLellan says: "The board is pleased with the outcome of the vote, which demonstrated a very strong support from the CREI shareholders and further derisks the execution of the recommended merger." Encourages API shareholders to vote in favour of the scheme.

----------

By Jeremy Cutler, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
2 Nov 2021 09:57

AIM WINNERS & LOSERS: Warpaint sees profit topping market forecasts

AIM WINNERS & LOSERS: Warpaint sees profit topping market forecasts

Read more
16 Sep 2021 18:19

IN BRIEF: ValiRx inks evaluation agreement for breast cancer treatment

IN BRIEF: ValiRx inks evaluation agreement for breast cancer treatment

Read more
7 Sep 2021 15:05

EARNINGS UPDATES: ValiRx reports narrowed loss; McBride revenue slips

EARNINGS UPDATES: ValiRx reports narrowed loss; McBride revenue slips

Read more
6 Jul 2021 13:00

ValiRx adds three new patents in first half

(Sharecast News) - Clinical-stage drug development company ValiRx updated the market on its patent portfolio on Tuesday, reporting that it had continued to build its intellectual property position in the first half of the year.

Read more
27 May 2021 20:17

TRADING UPDATES: Brave Bison, Strix Group see strong performances

TRADING UPDATES: Brave Bison, Strix Group see strong performances

Read more
27 May 2021 13:54

ValiRx terminates peptide drug candidate deal

(Sharecast News) - Clinical-stage drug development company ValiRx announced on Thursday that it has ended its agreement over the evaluation of the 'KTH222' peptide as a drug candidate for treating patients with ovarian cancer.

Read more
20 May 2021 16:07

UK shareholder meetings calendar - next 7 days

UK shareholder meetings calendar - next 7 days

Read more
28 Apr 2021 15:30

EXECUTIVE CHANGES: Ex-Coca-Cola exec, Cafe Rouge founder for Deliveroo

EXECUTIVE CHANGES: Ex-Coca-Cola exec, Cafe Rouge founder for Deliveroo

Read more
27 Apr 2021 11:32

TRADING UPDATES: Focusrite sales soar; Gaming Realms in Slingo boost

TRADING UPDATES: Focusrite sales soar; Gaming Realms in Slingo boost

Read more
15 Feb 2021 16:04

Physiomics and ValiRx enter new collaboration deal

(Sharecast News) - Oncology consulting company Physiomics has entered into a new agreement with clinical-stage drug development company ValiRx, it announced on Monday, superseding the agreement between the two companies, which was announced in September 2011.

Read more
15 Feb 2021 11:05

IN BRIEF: ValiRx Extends Collaboration Agreement With Physiomics

IN BRIEF: ValiRx Extends Collaboration Agreement With Physiomics

Read more
19 Jan 2021 16:53

IN BRIEF: ValiRx's VAL201 Patented For Treatment Of Metastatic Cancer

IN BRIEF: ValiRx's VAL201 Patented For Treatment Of Metastatic Cancer

Read more
10 Nov 2020 17:40

UK TRADING UPDATE SUMMARY: Newly-Listed Wheaton Reports Bumper Quarter

UK TRADING UPDATE SUMMARY: Newly-Listed Wheaton Reports Bumper Quarter

Read more
23 Sep 2020 19:09

UK TRADING UPDATE SUMMARY: Joules In Lockdown Hit But Online Surges

UK TRADING UPDATE SUMMARY: Joules In Lockdown Hit But Online Surges

Read more
7 Sep 2020 11:55

ValiRx Loss Narrows In First Half Amid Reduction In Expenses

ValiRx Loss Narrows In First Half Amid Reduction In Expenses

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.